Glenmark Pharmaceuticals Ltd Financials
Company Logo

Glenmark Pharmaceuticals Ltd Financial Statement

Glenmark Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue2719.18
Operating Expense1857.47
Net Profit595.06
Net Profit Margin21.88
Earning Per Share21.09
EBIDTA800.17
Effective Tax Rate16.07

Glenmark Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual7,891.12
Operating Expenses Annual6,649.46
Operating Profit Annual7,480.02
Interest Annual277.11
Depreciation202.16
Net Profit Annual5,167.29
Tax Annual1,833.46

Glenmark Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning92.70
Cash Flow from Operations-495.45
Cash Flow from Investing3,197.17
Cash Flow from Financing-2,666.45
Cash Flow at the End127.96

Glenmark Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)30.54
PBIT Margin (%)27.98
PBT Margin (%)27.88
Net PROFIT Margin (%)65.48
Return On Networth / Equity (%)6.98
Return On Networth /Employed (%)9.75
Return On Assets (%)22.92
Total Debt / Equity (X)0.10
Asset Turnover Ratio (%)0.35

Glenmark Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,778.42
Total Current Assets Annual4,681.47
Non Current Assets Annual22,732.92
Total Shareholders Funds Annual22,970.62
Total Assets Annual27,414.39

Glenmark Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

12.55

Reported

12.55

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Dec 5, 2024, Glenmark Pharmaceuticals Ltd has a market capitalization of 27,019.52 Cr. Value Research classifies it as a Large-Cap company.
Yes, Glenmark Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.03.
In FY 2023 , Glenmark Pharmaceuticals Ltd recorded a total revenue of approximately 7,649.76 Cr marking a significant milestone in the company's financial performance.
Glenmark Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and -0.0% annually, respectively..
Glenmark Pharmaceuticals Ltd's current PE ratio is 5.23.
Glenmark Pharmaceuticals Ltd's ROCE averaged 10.1% from the FY ending March 2022 to 2024, with a median of 10.4%. It peaked at 10.6% in March 2023, reflecting strong capital efficiency over the period..
Glenmark Pharmaceuticals Ltd's latest EBIT is Rs. 7,277.86 Cr, surpassing the average EBIT of Rs. 3,876.68 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions